CA2907079C - Combination of canagliflozin and probenecid for the treatment of hyperuricemia - Google Patents

Combination of canagliflozin and probenecid for the treatment of hyperuricemia Download PDF

Info

Publication number
CA2907079C
CA2907079C CA2907079A CA2907079A CA2907079C CA 2907079 C CA2907079 C CA 2907079C CA 2907079 A CA2907079 A CA 2907079A CA 2907079 A CA2907079 A CA 2907079A CA 2907079 C CA2907079 C CA 2907079C
Authority
CA
Canada
Prior art keywords
canagliflozin
probenecid
therapy
amount
hyperuricemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2907079A
Other languages
English (en)
French (fr)
Other versions
CA2907079A1 (en
Inventor
Paul ROTHENBERG
Douglas K. Ways
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA2907079A1 publication Critical patent/CA2907079A1/en
Application granted granted Critical
Publication of CA2907079C publication Critical patent/CA2907079C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2907079A 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treatment of hyperuricemia Active CA2907079C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786738P 2013-03-15 2013-03-15
US61/786,738 2013-03-15
PCT/US2014/020958 WO2014149789A1 (en) 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treament of hyperuricemia

Publications (2)

Publication Number Publication Date
CA2907079A1 CA2907079A1 (en) 2014-09-25
CA2907079C true CA2907079C (en) 2021-06-22

Family

ID=50483479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907079A Active CA2907079C (en) 2013-03-15 2014-03-06 Combination of canagliflozin and probenecid for the treatment of hyperuricemia

Country Status (6)

Country Link
US (2) US20160022632A1 (https=)
EP (1) EP2968235B1 (https=)
JP (2) JP2016512817A (https=)
CA (1) CA2907079C (https=)
ES (1) ES2647526T3 (https=)
WO (1) WO2014149789A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105548378B (zh) * 2015-12-03 2017-12-26 上海应用技术学院 一种卡格列净α、β异构体的分离方法
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
US11547685B2 (en) * 2017-12-11 2023-01-10 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
SG11202105743RA (en) * 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
MX2021009755A (es) * 2019-02-13 2021-11-17 Iterum Therapeutics International Ltd Combinaciones de compuestos beta-lactámicos y probenecid, y usos de los mismos.
CN111057049B (zh) * 2019-11-18 2021-06-01 杭州华东医药集团新药研究院有限公司 一种卡格列净半水化合物的制备方法
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
CN112957318A (zh) * 2021-02-02 2021-06-15 河北科星药业有限公司 丙磺舒溶液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US8791077B2 (en) * 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
EP2552442A1 (en) * 2010-03-30 2013-02-06 Boehringer Ingelheim International GmbH Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof

Also Published As

Publication number Publication date
EP2968235A1 (en) 2016-01-20
US20160022632A1 (en) 2016-01-28
WO2014149789A1 (en) 2014-09-25
JP2019089825A (ja) 2019-06-13
EP2968235B1 (en) 2017-09-13
CA2907079A1 (en) 2014-09-25
US20170368025A1 (en) 2017-12-28
ES2647526T3 (es) 2017-12-22
JP2016512817A (ja) 2016-05-09

Similar Documents

Publication Publication Date Title
CA2907079C (en) Combination of canagliflozin and probenecid for the treatment of hyperuricemia
CN102834099B (zh) Dgat1抑制剂的用途
EP2291189B1 (en) Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
US7834056B2 (en) Pharmaceutical composition for gout
CA2737163C (en) Methods of treatment of hyperuricemia and associated disease states
HK1248124A1 (zh) 用於治疗肥胖症和肥胖症相关疾病的包含卡格列净和芬特明的协同治疗
Wehring et al. Diabetes mellitus associated with clozapine therapy
WO2002078692A1 (en) Method of treatment
US20070287685A1 (en) Medicinal composition containing FBPase inhibitor
TW202103709A (zh) 用於治療患有慢性腎臟病之對象的方法
US20070259928A1 (en) Medicinal Composition for Treating Diabetes
WO2007007757A1 (ja) PPARγアゴニストを含有する医薬組成物
WO2024141073A1 (en) Pharmaceutical combinations and compositions, and methods of use thereof
JPH01216931A (ja) 血中尿酸濃度低減用治療剤
Hassan Drugs Used in GOUT
WO1999007412A1 (en) Remedies for diseases associated with bone resorption
HK1104477A (en) Medicinal composition containing fbpase inhibitor
HK1080381A (en) Drug composition for prevention or inhibition of advance of diabetic complication

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241217

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260203